Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T., Srinivas, S., Rosenberg, J. E., Guseva, M., Yu, Y., Narayanan, S., Hoimes, C. J. LIPPINCOTT WILLIAMS & WILKINS. 2022
View details for DOI 10.1200/JCO.2022.40.6_suppl.435
View details for Web of Science ID 000771008900441